You are here

UC-Irvine Researchers Shift Focus to Inflammatory Aspects of Alzheimer's

Rodent model suggests that TOM-1 protein may control key step in inflammatory underpinnings

Biologists at the University of California-Irvine have trained their sights on the inflammatory aspects of Alzheimer's disease as way to possibly derail the pathology of the brain disease.

In a paper recently published in Proceedings of the National Academy of Sciences, researchers at the university’s School of Biological Sciences say the role of a protein called TOM-1 may help rebalance Alzheimer's research toward the inflammatory processes that underlie the disease. Their findings come from a rodent model of the Alzheimer's, so they must be viewed as preliminary.

“Scientists have known for a long time that inflammation is a driver of Alzheimer’s disease,” said Frank M. LaFerla, Ph.D., the school’s dean and whose laboratory conducted the research. “But inflammation is complex and involved many factors. That’s why we decided to look at TOM-1.”

TOM-1 helps regulate a key component of the inflammatory response, but its role in the Alzheimer’s has largely been unexplored, explained Alessandra C. Martini, Ph.D., the paper’s first author and post-doctoral researchers in the lab.

“We were interested in TOM-1 because its levels are low in the Alzheimer’s brain and in the brains of Alzheimer’s rodent models,” Martini said.

The scientists found that reducing the amount of TOM-1 in Alzheimer’s rodent models increased pathology and inflammation and exacerbated cognitive problems associated with the disease. When TOM-1 levels were restored, the effects were reversed.

“You can think of TOM-1 as being like the brakes of a car and the brakes aren’t working for people with Alzheimer’s,” LaFerla said. “This research shows that fixing the brakes at the molecular level could provide an entirely new therapeutic avenue.”

Source: UCI News, September 30

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs